CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 403 enrolled / 403 target
Drug / intervention
DPP-GLB Standard +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04757519
NCT04757519N/ACompletedMonitor (6.3/mo)Completion was 18mo ago

Enhancing the Diabetes Prevention Program to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.

Lovoria Williams·interventional·Posted Feb 17, 2021·Updated Jun 24, 2026

In Brief

A clinical study evaluating DPP-GLB Standard and DPP-GLB Enhanced for Diabetes. Completed, enrolled 403 participants across 21 sites.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This study seeks to establish the efficacy of identifying weight loss nonresponders early in a Diabetes Prevention Program (DPP) intervention in 20 community settings (primarily churches and community centers) and providing them with individual-level, enhanced treatment through telephone contacts and access to additional resources. Additionally, potential mediators and moderators of the relationship between intervention status and weight loss response at 6 months in both nonresponders and responders will be examined and a cost-effectiveness analysis to evaluate the cost of the intervention will be conducted. This study addresses key gaps in the literature about the weight loss effects of identifying nonresponders early and characterizing individuals who need more intense personalized strategies. The investigators hypothesize that changes between baseline and 3 months will be more pronounced among the nonresponders in the intervention group compared to the nonresponders in the active control group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedFeb 17, 2021
Enrollment StartFeb 18, 2021
Primary CompletionDec 4, 2024
Study CompletionApr 17, 2026
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.4 years ago

Arms & Interventions

DPP-GLB Standardexperimental

Participants in this group will receive the standard Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.

Behavioral: DPP-GLB Standard
DPP-GLB Enhancedexperimental

Participants in this group will receive the enhanced Diabetes Prevention Program Group Lifestyle Balance (DPP-GLP) Intervention Program.

Behavioral: DPP-GLB Enhanced

Interventions

DPP-GLB Standardbehavioral

The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.

DPP-GLB Enhancedbehavioral

The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.